UAE Introduces New Multi-Authorized Agent Requirement for Pharmaceutical Products

The Emirates Drug Establishment (EDE) has activated a new regulatory mechanism requiring pharmaceutical companies to appoint more than one authorized agent for each medical product marketed in the United Arab Emirates.

This measure represents a significant regulatory development aimed at strengthening pharmaceutical supply security, improving market competition, and ensuring consistent access to medicines across the country.

The new regulation comes at a time when the UAE pharmaceutical sector is experiencing steady expansion. The national pharmaceutical market was valued at approximately USD 4.15–4.7 billion in 2024, with projections suggesting it could exceed USD 8 billion by 2033, growing at roughly 7% annually.

Key factors driving this growth include increased healthcare spending, the rising prevalence of chronic diseases, expanding healthcare infrastructure, and the continued development of medical tourism and advanced therapies.

Background: From Single Agent to Multi-Agent Model

Historically, pharmaceutical companies often relied on a single authorized agent to distribute each medical product within the UAE market. While this model provided clear accountability, it also created potential vulnerabilities if supply disruptions occurred.

Under the new mechanism announced by EDE, pharmaceutical companies must appoint multiple authorized agents for each product marketed in the UAE.

The system aims to break monopolistic distribution structures, diversify supply channels, and strengthen national pharmaceutical security while improving the availability of medicines.

Why This Change Matters

Global supply chain challenges in recent years have highlighted the importance of diversified distribution networks. For a healthcare market valued at several billion dollars and growing rapidly, uninterrupted access to medicines is critical.

The new regulatory approach is expected to deliver several benefits:

• Improved medicine availability across the country

• Reduced risk of shortages during emergencies or crises

• Greater flexibility for pharmaceutical manufacturers

• Enhanced market competition and distribution efficiency

What Companies Need to Do

Pharmaceutical companies operating in the UAE will need to review their regulatory and commercial frameworks to ensure alignment with the new requirement.

Key considerations may include:

• Appointing additional authorized agents where necessary

• Ensuring each agent complies with regulatory licensing requirements

• Maintaining clear responsibilities for regulatory compliance and pharmacovigilance

• Establishing effective coordination between multiple agents and the marketing authorization holder

Looking Ahead

The introduction of the multi-agent system reflects the UAE’s broader commitment to building a robust and resilient healthcare ecosystem.

As the pharmaceutical market continues to expand and diversify, regulatory innovation will play a critical role in maintaining patient access to safe and effective medicines.

Looking ahead, regulatory developments such as this demonstrate how authorities in the region are adapting policies to meet the evolving needs of healthcare systems and pharmaceutical markets.

As regulatory frameworks continue to evolve in the UAE and across the GCC, discussions on supply chain resilience, pharmaceutical security, and regulatory innovation will remain central to the regional regulatory dialogue.

For additional information or regulatory advisory support regarding this update, please visit:

www.pra-me.com